肠促胰岛素类药物的安全性评估  

Safety Evaluation of Incretin Drugs

作　　者：刘喜宝 王鑫[2] 杨汉煜 李艳玲 王彩霞 

机构地区：[1]石药集团中奇制药技术(石家庄)有限公司新型药物制剂与辅料国家重点实验室,石家庄050035 [2]河北医科大学第一医院

出　　处：《药物流行病学杂志》2014年第5期325-329,共5页Chinese Journal of Pharmacoepidemiology

基　　金：科技部"十一五"重大新药创制项目(编号:2010ZX09401-402)

摘　　要：肠促胰岛素类药物包括GLP-1受体激动剂和DPP-4抑制剂。由于本类药物不同于其他传统降糖药物的独特作用机制,近年来的研究及临床应用取得了飞速进展。但是,人体内多脏器表达GLP-1受体、DPP4的底物众多,长期应用肠促胰岛素类药物的安全风险尚存在不确定性。故本文分别从胰腺、甲状腺、心血管系统、消化系统等方面,对本类药物近期的安全性研究进行了综述和分析。结果提示本类药物治疗引发胰腺炎和肿瘤的潜在风险是目前临床最大的担忧,有必要对肠促胰岛素类药物的临床应用进行长期的监测,为临床应用的安全性提供可靠数据。Incretin drugs include GLP-1 receptor agonists and DPP-4 inhibitors. The research and clinical application for these drugs have been made rapid progresses in recent years because of their unique mechanism of action differing from other traditional anti-diabetic drugs. However, GLP-1 receptors express in many tissues, and DPP-4 substrates are nu- merous. Longterm use of incretin drugs maybe has safety risk. In this paper,we reviewed and analyzed the reverse effects of incretin drugs on pancreas, thyroid, cardiovascular system, digestive system, etc. The result showed that the pancreatitis and tumor were the biggest concern at present clinical. Therefore, it is necessary for us to pay long-term attention to the use of the incretin drugs, provide safety data for their clinical application.

关 键 词：肠促胰岛素 胰高血糖素样肽1受体激动药 二肽基肽酶Ⅳ抑制药 安全性评估 

分 类 号：R977.15[医药卫生—药品]